Tapentadol Extended ReleaseIn Adults with Chronic Pain

被引：0
|
作者：
Sheridan M. Hoy
机构：
[1] Adis,
来源：
Drugs | 2012年 / 72卷
关键词：
Immediate Release; Maintenance Period; Tapentadol; Pain Intensity Score; Nonblind Study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The extended release (ER; as ascribed in the US) or prolonged release (PR; as ascribed in Europe) formulation (hereafter referred to as ER) of the oral analgesic tapentadol is believed to exert its analgesic effects via m-opioid receptor agonistic and norepinephrine reuptake inhibitory activity. Direct conversion between tapentadol immediate release and tapentadol ER is permissible utilizing approximately equivalent total daily doses.
引用
收藏
页码：375 / 393
页数：18
相关论文
共 50 条
  • [21] Dalfampridine Extended ReleaseIn Multiple Sclerosis
    Claudine M. Chwieduk
    Gillian M. Keating
    CNS Drugs, 2010, 24 : 883 - 891
  • [22] Tapentadol in the treatment of tumor-related chronic pain
    Dzierzanowski, Tomasz
    Cialkowska-Rysz, Aleksandra
    MEDYCYNA PALIATYWNA-PALLIATIVE MEDICINE, 2016, 8 (04): : 157 - 163
  • [23] Unique pharmacology of tapentadol for treating acute and chronic pain
    Knezevic, Nebojsa Nick
    Tverdohleb, Tatiana
    Knezevic, Ivana
    Candido, Kenneth D.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2015, 11 (09) : 1475 - 1492
  • [24] A SYSTEMATIC REVIEW OF TAPENTADOL IN CHRONIC MODERATE TO SEVERE PAIN
    Riemsma, R.
    Forbes, C.
    Harker, J.
    Misso, K.
    Liedgens, H.
    Schaefer, M.
    Kleijnen, J.
    VALUE IN HEALTH, 2011, 14 (07) : A411 - A411
  • [25] US FDA approve tapentadol extended-release tablets for the treatment of moderateto-severe chronic pain
    不详
    PAIN MANAGEMENT, 2011, 1 (06) : 500 - 500
  • [26] Prediction of response to tapentadol in chronic low back pain
    Reimer, M.
    Huellemann, P.
    Hukauf, M.
    Keller, T.
    Binder, A.
    Gierthmuehlen, J.
    Baron, R.
    EUROPEAN JOURNAL OF PAIN, 2017, 21 (02) : 322 - 333
  • [27] Population Pharmacokinetic Modeling of Tapentadol Extended Release (ER) in Healthy Subjects and Patients with Moderate or Severe Chronic Pain
    Huntjens, Dymphy R.
    Liefaard, Lia C.
    Nandy, Partha
    Drenth, Henk-Jan
    Vermeulen, An
    CLINICAL DRUG INVESTIGATION, 2016, 36 (03) : 213 - 223
  • [28] Population Pharmacokinetic Modeling of Tapentadol Extended Release (ER) in Healthy Subjects and Patients with Moderate or Severe Chronic Pain
    Dymphy R. Huntjens
    Lia C. Liefaard
    Partha Nandy
    Henk-Jan Drenth
    An Vermeulen
    Clinical Drug Investigation, 2016, 36 : 213 - 223
  • [29] Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy
    Niesters, M.
    Proto, P. L.
    Aarts, L.
    Sarton, E. Y.
    Drewes, A. M.
    Dahan, A.
    BRITISH JOURNAL OF ANAESTHESIA, 2014, 113 (01) : 148 - 156
  • [30] Efficacy of Tapentadol ER for Managing Moderate to Severe Chronic Pain
    Afilalo, Marc
    Morlion, Bart
    PAIN PHYSICIAN, 2013, 16 (01) : 27 - 40
12345